GleamWall
中文EN

EVFM Evofem Biosciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1618835 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.0%
TTM net income YoY-133.9%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR9.3%
Net income 3-yr CAGR—

Margins

Gross margin75.9%
Operating margin-16.8%
Net margin-71.7%
FCF margin—
EBITDA margin-16.7%

Returns

ROE—
ROA-120.6%
ROIC (approx.)—
Asset turnover1.68x

Leverage & solvency

Liabilities / assets1,184.7%
Debt / equity—
Current ratio0.07x
Interest coverage-1.18x

Cash quality & payout

Operating cash flow / net income0.05x
Accruals ratio-115.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$20.18M$19.36M
Cost of revenue$4.62M$3.83M
Gross profit$15.57M$15.53M
R&D expense—$1.84M
SG&A expense$7.39M$11.56M
Operating income$3.37M-$7.68M
Interest expense$2.37M$2.24M
Pretax income$393,000-$8.86M
Income tax$2,000—
Net income$391,000-$8.86M
EBITDA$3.39M-$7.65M
EPS (basic)0.00-0.11
EPS (diluted)0.00-0.11
Weighted avg. shares (diluted)6.42B80.00M
Balance sheet
Cash & equivalents$578,000$741,000
Receivables$12.48M$9.83M
Inventory$1.13M$1.58M
Current assets$15.28M$13.61M
PP&E, net$418,000$458,000
Intangibles$4.35M$9.60M
Total assets$20.27M$23.79M
Current liabilities$84.82M$80.45M
Short-term debt$147,000$135,000
Total liabilities$89.71M$90.26M
Shareholders' equity-$74.34M-$71.26M
Shares outstanding126.69M113.36M
Cash flow statement
Operating cash flow-$1.99M-$3.88M
Capital expenditure$5,000$14,000
Free cash flow-$2.00M-$3.90M
Investing cash flow-$62,000-$569,000
Financing cash flow$1.89M$4.62M
Depreciation & amortization$19,000$30,000
Stock-based compensation$166,000$847,000

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.